Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT06446661
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • High Intensity — OTHER
    Daily texts
  • No Text Messagings — OTHER
    Standard Care
  • Low Intensity Text Messaging — OTHER
    Weekly Texts

Study Details

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

Key Dates

First listed
Jun 6, 2024
Start date
May 19, 2026
Status verified
Jul 2026
Primary completion
Jun 15, 2027
Completion
Jun 15, 2028

Study Design

Enrollment
48 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Efficacy Phase: High Intensity Messaging
    Receives high-intensity text messaging for 2 cycles of treatment
  • Active Comparator: Efficacy Phase: Low Intensity Messaging
    Receives no texts for 1st cycle and low-intensity texts for 2nd cycle
  • Experimental: Pilot Phase Arm
    Participants receive high-intensity text messaging for 28 days

Primary Outcome Measure

To compare adherence to oral chemotherapy between study groups for first treatment cycle (Efficacy Phase) [ Time Frame: 84 days after completion of enrollment to efficacy phase of study ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Medicine Comprehensive Cancer CenterChicagoIllinois60637
Clinical Trials Intake
[email protected]
855-702-8222
Austin Wesevich (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
University of Chicago Medicine Comprehensive Cancer Center· Chicago, IL

Related Studies